Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Record date for dividend and prospectus for listing of Alleima AB

The 2022 Annual General Meeting of Sandvik AB decided to distribute all shares of Sandvik’s subsidiary Alleima AB to the shareholders of Sandvik and to authorize the Board of Directors of Sandvik to determine the record date for the distribution. The Board of Directors of Sandvik has today set the record date to August 29, 2022. Nasdaq Stockholm’s Listing Committee has resolved to admit Alleima shares to trading and the first day of trading in Alleima is expected to be August 31, 2022. The prospectus relating to the admission to trading of Alleima shares on Nasdaq Stockholm is expected to

Optomed’s financial reporting in 2023

Optomed Plc Stock Exchange Release 4 August 2022 at 9.05, Helsinki Optomed’s financial reporting in 2023 Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2023 as follows: · Financial Statement Bulletin for 1 January – 31 December 2022, 17 February 2023 · Interim Report for 1 January – 31 March 2023, 5 May 2023 · Half-Year Financial Report for 1 January – 30 June 2023, 4 August 2023 · Interim Report for 1 January – 30 September 2023, 3 November 2023 Annual Report 2022, which includes the company’s financial

Sweco selected as adviser for one of the world’s first energy islands

Over the next nine years, Sweco will assist the Danish Energy Agency with technical advice on Denmark’s planned energy island in the North Sea, which will be one of the first of its kind. The agreement is valued at 500 MSEK with a cap of 830 MSEK.The Danish Energy Agency’s aim for the planned energy island is to ensure that the country can harvest its unique offshore wind resources in the best possible way and establish a role model for the green transition globally. “The energy transition is one of today’s greatest and most important challenges that is creating and will continue to

Read original

NNT and Polygiene team up to create new frontline workwear uniforms for health professionals

If you work in a high-pressure environment, you want to feel fresh and comfortable. When it’s a medical or care workplace, the added advantage of clothing that’s not just smart but also inhibits bacterial growth is obvious. To tick all these boxes, NNT and Polygiene have teamed up to create a new range of protective uniforms and scrubs for health professionals.The new workwear, marketed under the Workwear Group logo, incorporates Polygiene’s innovative StayFresh™ technology. StayFresh specifically works to inhibit the growth of odor-causing bacteria in fabric. Polygiene’s principle of “Wear

Lynparza approved in EU for early breast cancer

4 August 2022 07:00 BST   Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer   First and only approved medicine targetingBRCA mutations in early breast cancer  AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer

News conference on Kojamo’s Half-Year Report for January–June 2022 on 18 August 2022

Kojamo plc Press Release4 August 2022 at 9:00 a.m. EEST News conference on Kojamo’s Half-Year Report for January–June 2022 on 18 August 2022 Kojamo plc’s Half-Year Report for January–June 2022 will be published on Thursday, 18 August 2022 at approximately 8:00 a.m. EEST. News conference and webcast Kojamo will hold a news conference for institutional investors, analysts and media on 18 August 2022 at 10:00 a.m. at its headquarters at Mannerheimintie 168A, Helsinki, Finland. The event will be hosted by Kojamo’s CEO Jani Nieminen and CFO Erik Hjelt, and it will be held in

Herantis Pharma: Invitation to 1H 2022 Report on August 25, 2022

Herantis Pharma Plc, Press Release, August 4, 2022 at 09:00 EEST Herantis Pharma Plc("Herantis") an innovative biotech company developing new disease modifying therapies for Parkinson's disease, announced today that it will release 1H 2022 Report on Thursday August 25, 2022, at 08:00 EEST/ 07:00 CEST. Members of the Herantis’ Management team will hold a live webinar to provide more details on the 1H 2022 Report with a live Q&A session (in English) for investors, analysts, and media at 10:00 EEST / 9:00 CEST. Please join the webinar a few minutes in advance. Registration details:

Moberg Pharma and Padagis sign agreement for MOB-015 in Israel

STOCKHOLM, August 4[th], 2022, Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.Padagis will conduct registration activities in Israel, and will be marketing, distributing and selling MOB-015 in Israel and the Palestinian territories upon completion of registration. “This is the sixth commercial

UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis

· ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase 3 studies · AD is the most common chronic inflammatory skin disease in the developed world · Orismilast is a next generation PDE4 inhibitor shown to be potent in inhibiting pathways important in AD · Orismilast MR tablet is also in development for the treatment of psoriasis and hidradenitis suppurativa (HS) Hellerup, Denmark, 4 August 2022 – UNION therapeutics A/S (UNION), a

Invitation to John Mattson’s presentation of the interim report Q2 2022 on 18 August at 11:00 am (CEST)

Invitation by John Mattson to the teleconference and webcast on Thursday 18 August at 11:00 a.m. (CEST) being held in conjunction with the publication of the company’s interim report for January-June 2022 at 8:00 a.m. (CEST) the same date.Investors, asset managers, equity analysts, the press and other stakeholders are invited to participate in the conference, where CEO Per Nilsson and CFO Mattias Lundström will present and comment on the period and result for Q2 2022. No advance notice of attendance is required. Following the presentation, it will be possible to ask questions. The

Tecnotree Corporation Financial Report for Q2 and Half Year 2022

Tecnotree Corporation Stock Exchange Release 4 Aug 2022 at 9:00 EETHealthy Order Book and Revenue Growth Second quarter (April – June 2022) · Net sales EUR 18.3 (16.7) million. · Operating result EUR 5.1 (7.6) million. · Result for the period EUR 4.0 (5.3) million. · Cash flow after investments EUR -2.1 (1.8) million. · Earnings per share EUR 0.01 (0.02). · Order book at the end of the period EUR 72.8 (55.0) million. First half (January - June 2022) · Net sales EUR 31.6 (27.9) million. · Operating result EUR 7.1 (10.6) million. · Result for the period

Invitation to Q2 Earnings Teleconference

Karnov Group (Nasdaq: KAR) will publish its financial report for the second quarter and first six months 2022 on 18 August at around 08.00 a.m. CEST and Management will host a webcasted telephone conference the same day at 09.00 a.m. CEST.Karnov Group’s half-year report for the period January – June 2022 will be published on Thursday 18 August 2022 at around 8.00 a.m. CEST. A webcasted telephone conference will be held at 09.00 a.m. CEST the same day, where CEO Pontus Bodelsson and CFO Jonas Olin will present the report and answer questions. You can follow the presentation via webcast

Optomed Plc: Half-year financial report, January – June 2022

Optomed Plc Stock Exchange Release 4 August 2022 at 9.00, Helsinki    Optomed Plc: Half-year financial report, January – June 2022 April – June 2022   · Revenue decreased by 7.0 percent to EUR 3,7 (4,0) million. · Devices segment revenue decreased by 28.2 percent to EUR 1,4 (1,9) million as the revenue from China declined over 90% whereas the rest of the world grew over 40%. · Software segment revenue increased by 12.1 percent to EUR 2,4 (2,1) million. · Adjusted EBITDA amounted to EUR -813 (177) thousand corresponding to -21.8 (4.4) percent of revenue. ·

Outokumpu half-year report January–June 2022: Adjusted EBITDA in the second quarter exceeded EUR 0.5 billion

Outokumpu OyjHalf-year reportAugust 4, 2022 at 9.00 am EESTOutokumpu half-year report January–June 2022: Adjusted EBITDA in the second quarter exceeded EUR 0.5 billion Highlights in Q2 2022 · Stainless steel deliveries were 603,000 tonnes (626,000 tonnes)1. · Adjusted EBITDA increased to EUR 547 million  (EUR 223 million). · EBITDA was EUR 547 million (EUR 223 million). · Return on capital employed increased to 29.9% (5.2%) · Operating cash flow amounted to EUR 104 million (EUR 6 million). · Net debt decreased to EUR 289 million (March 31, 2022: EUR 294 million).

Glaston’s financial reports in 2023

Glaston Corporation         Stock Exchange Release             4.8.2022 at 8.45Glaston Corporation will disclose the following financial reports in 2023: · Financial Statement Bulletin 2022, on Thursday, 9 February 2023 · Interim report January-March 2023, on Wednesday, 26 April 2023 · Half year financial report January-June 2023, on Tuesday, 1 August 2023 · Interim report January-September 2023, on Thursday, 26 October 2023 Glaston’s Financial Statements 2022 and Annual Report 2022 will be published latest in week 11. The Annual General Meeting is planned to take place on

Invitation to Readly’s Q2 presentation on 11 August

Readly will publish its interim report for the second quarter 2022 on 11 August at 07:30 CET. The report will be presented in an audiocast and teleconference at 09.00 CET the same day.Mats Brandt CEO and Johan Adalberth, CFO, will present the report and answer questions.The presentation will be held in English. To listen to the conference by phone, please call: SE: +46 8 505 163 86 UK: +44 20 3198 4884 US: +1 412 317 6300 Pin code: 5426959# Follow the presentation live on: Link to audio cast  Report and

Teleste: Half year financial report 2022 will be published on 11 August, 2022 – invitation to press briefing

Teleste CorporationPress releaseAugust 4, 2022, at 8:30 a.m. EEST  TELESTE: HALF YEAR FINANCIAL REPORT 2022 WILL BE PUBLISHED ON 11 AUGUST – INVITATION TO PRESS BRIEFINGTeleste will publish its half year financial report 1 January – 30 June 2022 as a stock exchange release on 11 August approx. at 08:30 a.m. EEST. A briefing for analysts, media, financial institutions and professional investors will be held virtually in Teams the same day at 09:30 a.m. EEST hosted by CEO, Mr Esa Harju and CFO, Mr Juha Hyytiäinen.  PRESS BRIEFING (held in Finnish):Date: Thursday, 11 August,

Glaston’s half-year financial report January─June 2022: Solid progress in the second quarter despite challenging environment

GLASTON CORPORATION            HALF-YEAR FINANCIAL REPORT            4.8.2022 AT 8.30This release is a summary of Glaston Corporation's Half-Year January-June 2022 financial report. The complete report is attached to this release as a pdf-file. The release is also available on the company's website at the address www.glaston.net.    APRIL–JUNE 2022 IN BRIEF · Orders received totaled EUR 56.2 (64.5) million · Net sales totaled EUR 53.5 (43.3) million · Comparable EBITA was EUR 3.5 (2.4) million, i.e. 6.6 (5.5)% of net sales · The operating result (

Nurminen Logistics Plc Half-Year Financial Report 1 January-30 June 2022

Nurminen Logistics Plc                                      Half-Year Financial Report 4 August 2022 at 8:30    This release is a summary of Nurminen Logistics' Half-Year Financial Report January-June 2022. The full report is attached to this stock exchange release and is available on Nurminen Logistics' website at https://nurminenlogistics.com/investors/publications/ Growth continued despite the war in Ukraine. Net sales increased by 14 per cent to EUR 71.7 million and the comparable operating profit adjusted for non-recurring items was EUR 4.6 million.   JANUARY-JUNE 2022

Vår Energi ASA: Ex dividend Q2 2022

Sandnes, Norway, 4 August 2022: The shares in Vår Energi ASA (OSE: VAR) will be traded ex dividend of NOK 1.025 per share for the second quarter of 2022, as of today, 4 August. With reference to the stock market announcement on 26 July, the Board of Vår Energi ASA resolved to pay a dividend payment of NOK 1.025 per share, NOK 2 558 816 402 in total, equal to USD 260 million relating to Q2 2022. The dividend will be paid in NOK and the NOK dividend amount is based on the daily exchange rate published by Norges Bank 25 July 2022 approximately at 1600hrs CEST. The dividend will be paid on

Invitation: Presentation of Ambea’s second quarter 2022 results

Hosts: Mark Jensen, CEO and Benno Eliasson, CFO.On August 18th at 07:00 (CET) Ambea will publish its’ second quarter 2022 results. In connection to the announcement, Ambea will host a telephone conference at 10:00 (CET) on Thursday, August 18th. The presentation will be held in English and also available as webcast on www.ambea.com or direct link: https://edge.media-server.com/mmc/p/ny5zzajx To ensure that you are connected to the conference call, please dial in at least ten minutes before the start of the conference call to register your attendance. Code for registration: 14 26 30 15

Caverion Corporation’s Half-year Financial Report for 1 January – 30 June 2022

Caverion Corporation Half-year Financial Report 4 August 2022 at 8.00 a.m. EESTCaverion Corporation’s Half-year Financial Report for 1 January – 30 June 2022 Organic revenue growth and margin improvement continued 1 April – 30 June 2022 · Revenue: EUR 577.0 (545.1) million, up by 5.9 (5.1) percent, 6.5 (2.6) percent in local currencies. Organic growth was 4.7 (3.3) percent. Services business revenue increased by 7.7 (10.1) percent, 8.3 (7.1) percent in local currencies. Projects business revenue increased by 2.5 (-2.9) percent, 3.1 (-4.6) percent in local currencies. ·

CapMan Plc 1–6 2022 Half-Year Report

CapMan Plc Stock Exchange Release / Half-Year Report4 August 2022 at 8:00 a.m. EEST CapMan Plc 1–6 2022 Half-Year Report Results and significant events in 1–6 2022: · Group turnover was MEUR 31.9 1 January–30 June 2022 (MEUR 23.2 1 January–30 June 2021) and increased by 38 per cent. · Operating profit was MEUR 33.0 (MEUR 21.5) and increased by 53 per cent. · Management Company business turnover was MEUR 26.2 (MEUR 18.9). Operating profit was MEUR 10.5 (MEUR 4.9). · Service business turnover was MEUR 5.7 (MEUR 4.2). Operating profit was MEUR 3.0 (MEUR 1.9). ·

Lehto Group Plc: Half-Year Financial Report 1 January–30 June 2022

Lehto Group PlcHalf Year Financial Report, 1 January-30 June 20224 August 2022 at 7.30 a.m. (EET)Significantly better financial position This half-year financial report has been prepared in accordance with the IAS 34 standard. The company complies with half-yearly reporting according to the Finnish Securities Markets Act. Figures in brackets refer to the corresponding period of the previous year, unless otherwise stated. Summary 1–6/2022 Group 4–6/ 4–6/ 1–6/ 2022 1–6/ 2021 1–12/ 2021 2022 2021Net sales from

There are no items matching the current filter
There are no more items matching the current filter
Back to top